Exactech (EXAC) Earns Daily Media Sentiment Score of 0.20

Press coverage about Exactech (NASDAQ:EXAC) has trended somewhat positive on Tuesday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exactech earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.1955829045693 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of research firms have recently issued reports on EXAC. BidaskClub upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Gabelli reiterated a “buy” rating on shares of Exactech in a research note on Monday, July 31st.

Exactech (EXAC) traded up 0.570% during mid-day trading on Tuesday, hitting $30.875. 23,002 shares of the stock were exchanged. The company has a 50 day moving average price of $29.64 and a 200 day moving average price of $28.73. Exactech has a 52 week low of $22.20 and a 52 week high of $31.90. The stock has a market cap of $442.99 million, a price-to-earnings ratio of 593.750 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The company’s revenue was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.31 earnings per share. Analysts expect that Exactech will post $1.29 EPS for the current fiscal year.

In other news, Director Fern Watts sold 1,013 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total transaction of $29,417.52. Following the completion of the transaction, the director now directly owns 4,727 shares in the company, valued at $137,272.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 28.30% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Exactech (EXAC) Earns Daily Media Sentiment Score of 0.20” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2017/09/12/exactech-exac-earns-daily-media-sentiment-score-of-0-20.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Insider Buying and Selling by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply